FGP
VERA icon

Freestone Grove Partners’s Vera Therapeutics VERA Stock Holding History

Freestone Grove Partners’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-146,097
Closed -$5.88M – 1335
2026
Q1 		$5.88M Buy
+146,097
New +$6.29M 0.04% 316

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Freestone Grove Partners's VERA Position: Q2 2026 in Review

Freestone Grove Partners sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 146,097 shares — an estimated $5.88M sold.

Freestone Grove Partners first reported a position in VERA in Q1 2026 and held it in 1 quarter. The position peaked at $5.88M in Q1 2026. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Freestone Grove Partners reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 146,097 Vera Therapeutics shares in Q2 2026, an estimated $5.88M.
  • Freestone Grove Partners first reported a position in Vera Therapeutics in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Vera Therapeutics position peaked at $5.88M in Q1 2026.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.